StockData
BioRestorative Therapies, Inc. logo

BioRestorative Therapies, Inc. (BRTX) stock

BRTXNasdaqServices-Misc Health & Allied Services, NECFiscal year ends December 31
Financials through Q1 FY2026, quarter ended Mar 31, 2026Last filing: 10-Q on May 14, 2026Score 8/30
$1.49−0.01 (-0.67%)

Close on Nov 13, 2026Market cap $37.96MP/E –Yield –

BioRestorative Therapies gross margin

Gross margin is gross profit as a percentage of revenue.

BioRestorative Therapies's gross margin for the twelve months ending Mar 31, 2026 was 92.1%. For fiscal 2025 it was 93.4%, against 93.0% the year before. The highest annual figure on record is 100.0% in fiscal 2017.

Annual gross margin

PeriodPeriod endValueChange (pts)
FY2025Dec 31, 202593.4%+0.4
FY2024Dec 31, 202493.0%−7.0
FY2023Dec 31, 2023100.0%+0.0
FY2017Dec 31, 2017100.0%+0.3
FY2016Dec 31, 201699.7%+41.3
FY2015Dec 31, 201558.4%+9.8
FY2014Dec 31, 201448.6%−39.0
FY2013Dec 31, 201387.6%−4.0
FY2012Dec 31, 201291.6%–

Quarterly gross margin

Change is against the same quarter a year earlier.

PeriodPeriod endValueChange (pts)
Q1 FY2026Mar 31, 202668.1%−20.2
Q4 FY2025Dec 31, 202591.7%−0.6
Q3 FY2025Sep 30, 202510.4%−81.8
Q2 FY2025Jun 30, 202597.1%+4.4
Q1 FY2025Mar 31, 202588.4%−11.6
Q4 FY2024Dec 31, 202492.3%−7.7
Q3 FY2024Sep 30, 202492.2%−7.8
Q2 FY2024Jun 30, 202492.7%−7.3
Q1 FY2024Mar 31, 2024100.0%+0.0
Q4 FY2023Dec 31, 2023100.0%+0.0
Q3 FY2023Sep 30, 2023100.0%+0.0
Q2 FY2023Jun 30, 2023100.0%+0.0
Q4 FY2017Dec 31, 2017100.0%+0.3
Q3 FY2017Sep 30, 2017100.0%+0.0
Q2 FY2017Jun 30, 2017100.0%+0.4
Q1 FY2017Mar 31, 2017100.0%–
Q4 FY2016Dec 31, 201699.7%–
Q3 FY2016Sep 30, 2016100.0%–
Q2 FY2016Jun 30, 201699.6%–

More BioRestorative Therapies figures

See a number that looks wrong?